Roche Holding Ltd (CH:RO)
:RO
Want to see CH:RO full AI Analyst Report?
RO Stock Chart & Stats
CHF335.20
-CHF4.40(-1.37%)
At close: 4:00 PM EST
CHF335.20
-CHF4.40(-1.37%)
Day’s Range― - ―
52-Week RangeCHF256.40 - CHF383.00
Previous CloseN/A
Volume5.14K
Average Volume (3M)28.08K
Market Cap
CHF262.98B
Enterprise ValueCHF288.18B
Total Cash (Recent Filing)CHF15.48B
Total Debt (Recent Filing)CHF31.64B
Price to Earnings (P/E)20.2
Beta1.27
Next Earnings
Jul 23, 2026EPS Estimate
10.06Next Dividend Ex-DateN/A
Dividend Yield2.88%
Share Statistics
EPS (TTM)16.18
Shares Outstanding106,691,000
10 Day Avg. Volume29,793
30 Day Avg. Volume28,076
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.08
Revenue Forecast (FY)CHF62.41B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow & ProfitabilityConsistent high operating cash flow and robust free cash flow provide durable funding for R&D, dividend increases and capital investment. Strong gross and EBIT margins support reinvestment capacity and financial resilience, enabling sustained product development and shareholder returns.
Deep, De‑risked Pharma PipelineA larger, advancing NME cohort plus multiple approvals materially raises the company’s risk‑adjusted future revenue potential. Progress across oncology, immunology and CNS increases probability of durable new product flows, supporting medium‑term revenue diversification beyond LOE exposures.
Diagnostics Installed Base & Product InnovationDiagnostics innovation (new assays, mass spec and high‑throughput NGS) expands addressable markets and supports recurring reagent and service revenue from installed instruments. Regulatory designations that broaden test access strengthen long‑term consumables annuity economics and clinical adoption.
Bears Say
China Diagnostics Pricing ReformsSustained Chinese healthcare pricing reforms are a structural headwind for diagnostics revenue and margins in a major market. Prolonged lower pricing and reimbursement can permanently reduce consumables ASPs and slow instrument placement economics, requiring margin and product mix offsets elsewhere.
Loss Of Exclusivity (LOE) & BiosimilarsMaterial LOE and impending biosimilar competition threaten recurring revenue from established brands. Revenue erosion from LOE is a multi‑year structural risk that pressures growth and forces reliance on new launches and the pipeline to replace lost cash flow and protect margins.
Elevated Leverage Vs. Prior YearsLeverage materially above historical lows reduces financial flexibility for large M&A, aggressive buybacks or cushioning cyclical shocks. While manageable, higher net debt increases interest and refinancing sensitivity, constraining tactical capital allocation if growth slows or cash conversion weakens.
Roche Holding Ltd News
RO FAQ
What was Roche Holding Ltd’s price range in the past 12 months?
Roche Holding Ltd lowest stock price was CHF256.40 and its highest was CHF383.00 in the past 12 months.
What is Roche Holding Ltd’s market cap?
Roche Holding Ltd’s market cap is CHF262.98B.
When is Roche Holding Ltd’s upcoming earnings report date?
Roche Holding Ltd’s upcoming earnings report date is Jul 23, 2026 which is in 37 days.
How were Roche Holding Ltd’s earnings last quarter?
Roche Holding Ltd released its earnings results on Jan 29, 2026. The company reported CHF8.375 earnings per share for the quarter, missing the consensus estimate of CHF8.515 by -CHF0.14.
Is Roche Holding Ltd overvalued?
According to Wall Street analysts Roche Holding Ltd’s price is currently Overvalued.
Does Roche Holding Ltd pay dividends?
Roche Holding Ltd pays a Annually dividend of CHF10.799 which represents an annual dividend yield of 2.88%. See more information on Roche Holding Ltd dividends here
What is Roche Holding Ltd’s EPS estimate?
Roche Holding Ltd’s EPS estimate is 10.06.
How many shares outstanding does Roche Holding Ltd have?
Roche Holding Ltd has 106,691,000 shares outstanding.
What happened to Roche Holding Ltd’s price movement after its last earnings report?
Roche Holding Ltd reported an EPS of CHF8.375 in its last earnings report, missing expectations of CHF8.515. Following the earnings report the stock price went up 1.79%.
Which hedge fund is a major shareholder of Roche Holding Ltd?
Currently, no hedge funds are holding shares in CH:RO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding Ltd
Roche Holding AG is a global healthcare enterprise with dual focuses: pharmaceuticals and diagnostics. The company maintains a significant presence in numerous countries, including its home base in Switzerland, alongside Germany, the United States, Austria, the Netherlands, the United Kingdom, France, Belgium, and various other international markets. Its pharmaceutical segment develops and supplies treatments for a wide spectrum of medical conditions, encompassing oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments, as well as specific therapies for anemia, dermatology, hemophilia, inflammatory and autoimmune conditions, and transplant patients. On the diagnostic front, Roche provides in vitro tests designed to identify various diseases like cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, in addition to supplying crucial diagnostic instruments and reagents. The company was founded in Basel, Switzerland, in 1896.
Technical Analysis
Options Prices
Currently, No data available
---